Recent News

• 11.25.2025 - Anaptys Announces Participation in December Investor Conferences
• 11.25.2025 - Anaptys Announces Participation in December Investor Conferences
• 11.21.2025 - Anaptys Announces $100 Million Stock Repurchase Plan
• 11.21.2025 - Anaptys Announces $100 Million Stock Repurchase Plan
• 11.21.2025 - Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
• 11.21.2025 - Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
• 11.10.2025 - Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
• 11.10.2025 - Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
• 11.04.2025 - Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
• 11.04.2025 - Anaptys Announces Participation in November Investor Conferences

Recent Filings

• 11.21.2025 - 8-K Current report
• 11.21.2025 - EX-99.1 EX-99.1
• 11.21.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - 8-K Current report
• 11.10.2025 - EX-99.1 EX-99.1
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]